Rhenman & Partners Asset Management AB - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 173 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.

Quarter-by-quarter ownership
Rhenman & Partners Asset Management AB ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2017$1,538,000
-30.2%
120,000
-29.4%
0.22%
-36.7%
Q1 2017$2,203,000
+23.9%
170,000
-5.6%
0.35%
+2.3%
Q4 2016$1,778,000
-99.9%
180,000
-28.0%
0.34%
-29.0%
Q3 2016$3,020,000,000
+139844.4%
250,0000.0%0.48%
+25.3%
Q2 2016$2,158,000
-47.1%
250,000
-42.0%
0.38%
-52.7%
Q1 2016$4,082,000
-42.5%
431,000
+5.1%
0.81%
-24.6%
Q4 2015$7,105,000
+207.6%
410,000
+138.4%
1.07%
+191.8%
Q3 2015$2,310,000
-40.5%
172,0000.0%0.37%
-21.0%
Q2 2015$3,884,000172,0000.47%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2017
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders